Plinabulin - BeyondSpring Pharmaceuticals

Drug Profile

Plinabulin - BeyondSpring Pharmaceuticals

Alternative Names: BPI 2358; NPI 2358

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer BeyondSpring Pharmaceuticals; National Cancer Institute (USA); Nereus Pharmaceuticals; University of Washington
  • Class Antineoplastics; Imidazoles; Piperazines; Small molecules
  • Mechanism of Action Guanine nucleotide exchange factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neutropenia; Non-small cell lung cancer
  • Preclinical Glioblastoma
  • Research Brain cancer
  • No development reported Solid tumours

Most Recent Events

  • 21 Jun 2018 BeyondSpring announces intention to submit an NDA to CFDA for Non-small cell lung cancer by first half of 2019
  • 21 Jun 2018 BeyondSpring plans phase I development for Immuno-oncology (Combination therapy) by second half of 2018
  • 17 May 2018 Efficacy data from a phase II trial in Neutropenia released by BeyondSpring
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top